Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$212.15 USD

212.15
642,643

+1.37 (0.65%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $211.69 -0.46 (-0.22%) 5:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks News

Alcon (ALC) Gains From Growing Market Demand, New Launches

Within Vision Care, Alcon (ALC) is registering solid growth, banking on strong sales of its contact lenses and ocular health products.

ZimVie (ZIMV) Progresses in Dental Space With Biotivity Launch

ZimVie's (ZIMV) Biotivity A/C Plus Membrane is a barrier membrane that contains an array of growth factors.

Walgreens Boots (WBA) Q4 Earnings Miss Estimates, Margins Down

Walgreens Boots (WBA) Q4 retail revenues are impacted by macroeconomic-driven consumer pressure and lower COVID-19 OTC test kit sales.

Here's Why You Should Hold on to Penumbra (PEN) Stock for Now

Investors are optimistic about Penumbra (PEN), driven by strong vascular and neuro businesses.

Hologic (HOLX) to Elevate OB-GYN Training With New Partnerships

Hologic's (HOLX) collaboration with AAGL and Inovus Medical is likely to optimize OB-GYN training for minimally invasive surgeries.

Here's Why Investors Should Buy Bruker (BRKR) Stock Now

The strong prospects of the BSI BioSpin and CALID group are likely to bode well for Bruker (BRKR) stock.

Neogen's (NEOG) Q1 Earnings Miss Estimates, Margins Rise

Neogen's (NEOG) Q1 Animal Safety business experiences continued destocking, with channel inventory levels reaching multi-year lows.

Haemonetics (HAE) Announces Agreement to Acquire OpSens

Haemonetics' (HAE) acquisition of OpSens will expand its leadership in the interventional cardiology market.

Here's Why You Should Invest in Boston Scientific (BSX) Now

Investors are optimistic about Boston Scientific (BSX) on consistent growth and upbeat guidance.

Alcon (ALC) Expands Optical Care Line With Latest Launch

Alcon's (ALC) new TOTAL30 Multifocal lens outwits digital device dryness by delivering nearly 100% water at the lens's surface via a patented Water Gradient Technology.

After Plunging -11.1% in 4 Weeks, Here's Why the Trend Might Reverse for Align Technology (ALGN)

The heavy selling pressure might have exhausted for Align Technology (ALGN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

Investors remain optimistic about Exact Sciences (EXAS) due to its strategic prioritization and positive solvency.

Reasons to Add Cardinal Health (CAH) in Your Portfolio

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

NextGen's (NXGN) AI-Based Ambient Assist to Expedite Care Plans

NextGen's (NXGN) Ambient Assist will help reduce significant time by summarizing appointments and preparing care plans using AI-driven technology in real time.

Thermo Fisher's (TMO) Strong End Markets and New Buyouts Aid

Thermo Fisher (TMO) is registering strong growth in the electron microscopy and chromatography and mass spectrometry businesses in the academic and government end market.

Hyperfine (HYPR) Progresses in MRI Space With Latest FDA Nod

Hyperfine's (HYPR) updated Swoop software is expected to make brain imaging more accessible and clinically relevant.

Indrajit Bandyopadhyay headshot

4 Stocks to Buy From the Prospering Dental Supplies Industry

Here we discuss four stocks from the Dental Supplies industry that are likely to earn wealth for investors. These include MCK, WST, ALGN and HSIC.

Here's Why You Should Retain Charles River (CRL) Stock Now

Investors are optimistic about Charles River (CRL) on robust RMS segment growth and upbeat guidance.

ResMed (RMD) Gains From Strong Device Sales Amid Macro Woes

ResMed's (RMD) respiratory care business continues to drive growth and the adoption of bilevel and other non-invasive ventilator solutions worldwide.

enVVeno (NVNO) Plans to Expedite enVVe Development for CVI

enVVeno (NVNO) notes that its capital position is now strong enough to begin the enVVe pivotal study.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

Investors are optimistic about Teleflex (TFX), led by growth in Vascular, Interventional and Surgical businesses.

DexCom (DXCM) to Launch Latest CGM System G7 in Canada

DexCom's (DXCM) G7 CGM System (launched in Canada) is expected to combine simplicity and power, thereby providing a better way to manage diabetes.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

Investors remain optimistic about Tandem Diabetes (TNDM), backed by strategic developments and innovative new launches.

Quest Diagnostics (DGX) to Boost Lab Services With New Pact

Quest Diagnostics (DGX) latest deal will boost dialysis laboratory testing and reduce the laboratory costs of dialysis programs for ESRD patients.

Here's Why You Should Add McKesson (MCK) to Your Portfolio

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.